From the CDC supporting pretesting prior to rituxan

Atualização do abaixo-assinadoContinue to allow medical testing for virus and infection for the immune suppressedFrom the CDC supporting pretesting prior to rituxan

eugene desotellspotsylvania, VA, Estados Unidos

7 de out. de 2021

The CDC- Persons receiving cytotoxic or immunosuppressive therapy. Persons receiving cytotoxic or immunosuppressive therapy (e.g., chemotherapy for malignant diseases, immunosuppression related to organ transplantation, and immunosuppression for rheumatologic and gastroenterologic disorders) should be tested for serologic markers of HBV infection (i.e., HBsAg, anti-HBc, and anti-HBs). Prophylactic antiviral therapy can prevent reactivation in HBsAg-positive patients (13,101).

Copiar link

Facebook

Nextdoor

E-mail

Request for change in Local coverage determination

FDA requires prescreening prior to rituxan called drug induced Hepatitis